Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Icotrokinra (JNJ-2113) is the first oral IL-23 receptor peptide inhibitor in Phase III for psoriasis. Explore J&J's patent strategy and the race to challenge injectable biologics.
Article | Report Iptacopan vs. ravulizumab in PNH: how oral Factor B inhibition reshapes complement therapy, hemoglobin endpoints, and the competitive landscape.
Article | Report How GSK depemokimab and tezepelumab are reshaping severe asthma treatment beyond eosinophil-high phenotypes — a deep dive into the alarmin axis competitive race.
Article | Report How amivantamab redefined EGFR exon 20 insertion NSCLC treatment — and why the HER2 pipeline is racing to replicate that blueprint. Patent and clinical data analysis.
Article | Report How luspatercept's ActRIIB ligand trap and BMS's emerging RSK3 inhibitors are redefining anemia treatment in lower-risk MDS and beta-thalassemia beyond transfusion dependence.
Article | Report How AI-based optical emission spectroscopy improves real-time process control in plasma etching — what semiconductor fabs need to know before the data is in.
Article | Report Next-generation GLP-2 analogs are reshaping short bowel syndrome treatment beyond teduglutide. Explore the patent pipeline, key players, and what comes next.
Article | Report How engineers manage version control and traceability for safety-critical embedded software under IEC 62443 — key standards, lifecycle approaches, and toolchain best practices.
Article | Report Dato-DXd vs. SG in TNBC: compare TROP2 ADC mechanisms, linker-payload design, clinical signals, and IP landscape for datopotamab deruxtecan and sacituzumab govitecan.
Article | Report How does laser-based metal deposition compare to traditional welding for turbine blade tip restoration in MRO? Explore the key process differences, trade-offs, and patent trends.
Article | Report NLRP3 inhibitor VTX3232 is advancing toward Phase III in Parkinson's disease and cardiometabolic conditions — and Sanofi holds a right of first negotiation. Here's what the patent data reveals.
Article | Report How engineers use multi-physics co-simulation to design next-generation power electronic converters — thermal, EM, mechanical and circuit domain coupling explained.
Article | Report Fenebrutinib's Phase III trials in progressive MS target smoldering lesions via CNS-penetrant BTK inhibition. How does Roche's bet compare to tolebrutinib?
Article | Report How AI-powered generative design transforms the engineering workflow for lightweight satellite structural components — topology optimization, multi-objective automation, and manufacturing integration.
Article | Report TERN-701, Terns Pharmaceuticals' STAMP inhibitor targeting BCR-ABL's myristoyl pocket, prompted Merck's $6.7B acquisition. Explore the CML pipeline race.